ATE457318T1 - Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper - Google Patents

Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper

Info

Publication number
ATE457318T1
ATE457318T1 AT01273341T AT01273341T ATE457318T1 AT E457318 T1 ATE457318 T1 AT E457318T1 AT 01273341 T AT01273341 T AT 01273341T AT 01273341 T AT01273341 T AT 01273341T AT E457318 T1 ATE457318 T1 AT E457318T1
Authority
AT
Austria
Prior art keywords
directed against
human bst2
monoclonal antibod
bst2 antigen
antigen
Prior art date
Application number
AT01273341T
Other languages
English (en)
Inventor
Tomoyuki Tahara
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of ATE457318T1 publication Critical patent/ATE457318T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
AT01273341T 2000-12-28 2001-12-26 Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper ATE457318T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000403245 2000-12-28
PCT/JP2001/011493 WO2002057316A1 (fr) 2000-12-28 2001-12-26 Nouvel anticorps monoclonal

Publications (1)

Publication Number Publication Date
ATE457318T1 true ATE457318T1 (de) 2010-02-15

Family

ID=18867405

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01273341T ATE457318T1 (de) 2000-12-28 2001-12-26 Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper

Country Status (6)

Country Link
US (1) US7592005B2 (de)
EP (1) EP1354896B1 (de)
JP (1) JP4450555B2 (de)
AT (1) ATE457318T1 (de)
DE (1) DE60141297D1 (de)
WO (1) WO2002057316A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
NO347360B1 (no) * 2003-10-10 2023-09-25 Immunogen Inc Cellebindingsmiddelmaytansinoid-konjugat med formel trastuzumab-SMCC-DM1 eller trastuzumab-SIABDM1, fremgangsmåte for fremstilling av disse og en in vitro fremgangsmåte for å styre maytansinoider til en valgt cellepopulasjon eller for å eliminere celler, samt anvendelse.
CA2570602A1 (en) * 2004-06-11 2006-01-26 Ginkgo Biomedical Research Institute Co., Ltd. Agents for regulating the activity of interferon-producing cells
US20100143899A1 (en) * 2005-05-17 2010-06-10 University Of Vermont And State Agricultural College Methods and products for diagnosing cancer
CA2660795C (en) 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
US8445442B2 (en) * 2007-04-26 2013-05-21 University Of Vermont And State Agricultural College CCL18 and CCL3 methods and compositions for detecting and treating cancer
KR20100090258A (ko) * 2007-10-16 2010-08-13 에스비아이 바이오테크 가부시키가이샤 항ｂｓｔ2 항체
EP2638907A3 (de) 2008-03-18 2014-05-14 Genentech, Inc. Kombination aus einem Anti-HER2-Antikörperwirkstoffkonjugat und Lapatonib
SG191600A1 (en) * 2008-05-23 2013-07-31 Fit Biotech Oy Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant
JP5820800B2 (ja) 2010-03-02 2015-11-24 協和発酵キリン株式会社 改変抗体組成物
US20130259878A1 (en) * 2010-10-20 2013-10-03 Oxford Biotherapeutics Ltd Antibodies
CN107619443B (zh) * 2016-07-14 2020-08-14 深圳宾德生物技术有限公司 抗人和鼠cd317的单克隆抗体及其制备方法和应用
US20210330801A1 (en) 2017-03-02 2021-10-28 Cadila Healthcare Limited Novel protein drug conjugate formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
ES2241114T3 (es) * 1997-02-12 2005-10-16 Chugai Seiyaku Kabushiki Kaisha Anticuerpos como remedios para tumores linfociticos (excepto mieloma).
WO1998037913A1 (fr) * 1997-02-28 1998-09-03 Chugai Seiyaku Kabushiki Kaisha Inhibiteurs d'activation de lymphocytes
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JPH1192399A (ja) * 1997-09-24 1999-04-06 Chugai Pharmaceut Co Ltd 骨髄腫治療剤
ATE462975T1 (de) * 1998-02-25 2010-04-15 Chugai Pharmaceutical Co Ltd Verfahren zum immunochemischen testen des anti- hm1.24-antikörpers

Also Published As

Publication number Publication date
US20040136982A1 (en) 2004-07-15
DE60141297D1 (de) 2010-03-25
US7592005B2 (en) 2009-09-22
EP1354896A4 (de) 2004-06-16
EP1354896B1 (de) 2010-02-10
JP4450555B2 (ja) 2010-04-14
JPWO2002057316A1 (ja) 2004-05-20
WO2002057316A1 (fr) 2002-07-25
EP1354896A1 (de) 2003-10-22

Similar Documents

Publication Publication Date Title
CY2020003I2 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
ATE457318T1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
ATE389721T1 (de) Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen
DE60142342D1 (de) Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen
DE60142500D1 (de) Humane monoklonale Antikörper gegen das kostimulatorische Signaltransduktionsmolekül AILIM und pharmazeutische Verwendungen davon
ATE331529T1 (de) Antigen enthaltende pharmazeutische zusammensetzung
EA199800946A1 (ru) Концентрированный препарат антител
CR20120505A (es) Composición de fármaco conjugado
UY26807A1 (es) Anticuerpos de especificidad doble y métodos para la elaboración y el uso de los mismos
EA200100224A1 (ru) Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
MY162623A (en) Immunoglobulin formulation and method of preparation thereof
IS6779A (is) Mannlíkt mótefni gegn LT-beta-R
IT1318370B1 (it) Metodo e dispositivo per la diagnosi e la terapia dello scompensocardiaco cronico.
BR0317376A (pt) Anticorpo humanizado (h14.18) do anticorpo 14.18 do camundongo que se liga a gd2 e sua fusão com il-2
CY1106820T1 (el) Ανοσοδοκιμασιες για αντι-hcv αντισωματα
CY2010008I1 (el) Αντισωματα αντι-tnf, συνθεσεις, μεθοδοι και χρησεις
DE60238503D1 (de) Mit humanem cdr gepfropfte antikörper und antikörperfragmente davon
ATE426616T1 (de) Antikírper gegen menschliches mcp-1
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
DE60134324D1 (de) NEUE HEILMITTEL FüR KREBS
ATE407147T1 (de) Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein
DE3889062T2 (de) Monoklonaler Antikörper gegen humanen BCDF.
ATE226447T1 (de) Anti-fas antikörper gegen rheumatische krankheiten
DE60129278D1 (de) Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen
EE200100366A (et) Antikehade kasutamine vähivastase farmatseutilisekompositsiooni valmistamiseks

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties